Studies link GLP-1 drugs to a higher rate of hair loss, but they haven’t proven the drugs cause it, and the researchers behind the largest one describe the absolute risk as low. In that study, published in The BMJ, adults with type 2 diabetes who started a GLP-1 drug were diagnosed with hair loss more often than similar adults who started one of two other kinds of diabetes medication. The hazard ratios were 1.37 and 1.68, which works out to a rate roughly 37 percent and 68 percent higher. A separate analysis that pooled nine clinical studies found hair loss reported by 3.9 percent of people taking a GLP-1 drug. So the signal is real enough to know about, and by the researchers’ own description, small. If you take one of these drugs and your hair is thinning, tell your prescriber or a dermatologist.
The numbers, side by side
| What was compared | Result | In plain words |
| GLP-1 drug vs. an SGLT-2 inhibitor (BMJ study) | Hazard ratio 1.37 (95% confidence interval 1.08 to 1.73) | Hair loss was diagnosed at a rate about 37 percent higher in the GLP-1 group |
| GLP-1 drug vs. a DPP-4 inhibitor (BMJ study) | Hazard ratio 1.68 (1.28 to 2.20) | About 68 percent higher |
| Non-scarring hair loss only (BMJ study) | Hazard ratios 1.53 (1.18 to 1.97) and 1.72 (1.28 to 2.31) | The link showed up in this kind of hair loss specifically |
| GLP-1 drug vs. placebo (pooled analysis) | Risk ratio 3.252 (1.437 to 7.358) | Hair loss was reported about three times as often as on placebo |
| Everyone on a GLP-1 drug (pooled analysis) | 3.9 percent | About 4 people in every 100 reported hair loss |
A hazard ratio compares how often something happens in one group against another over the same stretch of time. A ratio of 1 means no difference. A ratio of 1.37 means 37 percent more, relative to the other group. It doesn’t tell you how many people that is, and that gap matters a lot here.
Who did the research, and how big was it?
The larger study came from a team at the University of Pennsylvania, including members of its dermatology department, and was published in The BMJ in July 2026. The work was supported by the National Institutes of Health. The researchers went through electronic health records from Penn Medicine and picked out adults with type 2 diabetes who started a new diabetes drug between January 2019 and September 2024.
They ran two comparisons. One set 12,004 people starting a GLP-1 drug against 15,221 starting an SGLT-2 inhibitor. The other set 11,964 people starting a GLP-1 drug against 11,238 starting a DPP-4 inhibitor. Both of those are other classes of diabetes medication. The team then counted who was later given a hair loss diagnosis, using the diagnostic codes in each chart, and adjusted the numbers statistically so the groups were as alike as possible at the start.
The second paper is a systematic review and meta-analysis, which means the authors gathered earlier studies and pooled their results. Two dermatologists at Taipei Medical University Hospital in Taiwan published it in Diabetes Research and Clinical Practice. They found nine studies that tracked hair loss in people given a GLP-1 drug: seven randomized controlled trials and two studies that weren’t randomized. Together those covered 4,114 people on a GLP-1 drug. Restricting the math to randomized trials in people with overweight or obesity gave a risk ratio of 3.587 (2.100 to 6.124). The authors declared no competing financial interests.
What “the absolute risk is low” means
This is the line from the BMJ authors that tends to get dropped. Their conclusion says GLP-1 use was associated with an increased risk of non-scarring hair loss in adults with type 2 diabetes, and then adds that the absolute risk is low.
Relative risk and absolute risk answer different questions. Relative risk says how much more often something happens in one group than another. Absolute risk says how often it happens at all. A 68 percent increase on a small number is still a small number. The study’s summary doesn’t give the raw counts, so we can’t tell you how many people out of every thousand were affected. What it does tell you is that the people who ran the numbers looked at them and chose the word “low.”
The 3.9 percent figure from the pooled analysis points the same way. Roughly 96 of every 100 people on a GLP-1 drug in those studies didn’t report hair loss.
What these studies can’t tell us
- Whether the drug is the cause. The BMJ study was observational. Nobody was randomly assigned to a medication; the researchers analyzed records of care that had already happened. That kind of study can show two things travel together. It can’t prove one causes the other.
- Whether it applies outside diabetes. Everyone in the BMJ study was an adult with type 2 diabetes. Someone taking a GLP-1 drug for weight management alone wasn’t in it.
- How it compares with taking nothing. The comparison was against two other diabetes drugs, not against no medication.
- Whether it holds beyond one health system. All of the records came from Penn Medicine.
- How much hair loss went unrecorded. The study counted diagnoses in a chart. Shedding that nobody mentioned to a clinician wouldn’t appear.
- How firm the size of the effect is. The link held up when the researchers re-ran the analysis in different ways, but it got weaker after one of their checks for hidden bias.
- Why it happens, or how long it lasts. Neither summary explains the reason, says whether the drug or the weight loss that comes with it is responsible, or reports whether hair grew back.
The pooled analysis has its own limits. Nine studies is a modest pile, and the range around its main result is wide, running from about 1.4 times to about 7.4 times. A wide range means the true figure is uncertain.
What “non-scarring” tells you
The BMJ team split hair loss into subtypes and found the link only in the non-scarring kind. Doctors use that term for hair loss in which the follicle, the tiny pocket in the scalp a hair grows from, stays intact. The study’s summary doesn’t narrow it further than that.
We’ve written about the delayed, all-over shedding that can follow a new prescription in our piece on when a medication is behind your hair shedding, including why it tends to show up months after the trigger and what to bring to an appointment. Our post on what rapid weight loss does to skin and hair covers shedding as a response to fast weight loss itself. The studies here don’t settle which of those explanations fits.
Hair care while you’re shedding
No shampoo, serum or styler stops a shed or regrows hair, and nothing in this table is a treatment. What hair care can do is keep your scalp comfortable, avoid breaking the hair you have, and make it look fuller on the days that bothers you. Wash on your usual schedule. Skipping washes doesn’t save hair; it just means more comes out at once when you do wash.
Prices move constantly, so we link to live listings instead of printing a number that is wrong by the time you read it. Links go to Amazon, which is where a referral gets credited.
Vanicream Shampoo is about $11, though the price changes often. It’s a non-medicated shampoo made for sensitive skin: fragrance-free and sulfate-free, with no botanical extracts or essential oils. If your scalp has turned touchy while you’re shedding, this is the plainest wash you can buy. Follow it with conditioner on the lengths.
The Ordinary Natural Moisturizing Factors + HA for Scalp is a light, milky serum for scalp dryness, at about $15. It has sodium hyaluronate, arginine and sodium PCA, and it’s free of alcohol, oil and silicone. The Ordinary says it won’t stick to hair or weigh it down. It’s moisturizer for your scalp, and that’s the whole job.
Aveeno Oat Milk Blend Shampoo is the pick if the Vanicream sounds too bare. It’s sulfate-free, with no dyes or parabens, and built around oat. Aveeno’s directions are to work it through wet hair to the ends, rinse well and follow with conditioner. About $17.
Act+Acre Daily Hydro Scalp Serum is a leave-on with hyaluronic acid, amino acids and glycerin, at about $24 for one ounce. Act+Acre says to put three or four droppers on a clean scalp, damp or dry, massage it in and not rinse. It covers the same ground as The Ordinary’s serum in a smaller bottle for more money, so buy it only if you want a few drops a day instead of a milky lotion.
Living Proof Full Thickening Blow-Dry Cream is the styler here, and at about $34 the most expensive pick. It’s a lightweight, silicone-free cream with heat protection up to 450°F, made for fine, thin or low-density hair. It goes on clean, damp hair from the mid-lengths to the ends before you blow-dry with a round brush. The effect is cosmetic and lasts until your next wash, which is exactly what you want from it.
If I Were You
If you take a GLP-1 drug and haven’t noticed any change in your hair, there’s nothing to do. The studies describe a low risk, not a likely outcome.
If you’re shedding more than usual, write down when you started the medication, when the shedding began and how much weight you’ve lost, and take that to your prescriber or a dermatologist. Don’t stop or change the dose yourself.
If you’re about to start one and hair is on your mind, say so at the appointment. Take a photo of your part in good light so you have something to compare against later.
If your scalp feels dry or sore, switch to the Vanicream and add The Ordinary’s scalp serum. That’s about $25 for both.
If the thinning shows and it’s getting to you, the Living Proof cream and a round brush will do more for how your hair looks in the mirror than any supplement aisle.
If hair is coming out in patches, or your scalp burns, hurts or scales, book a dermatologist promptly instead of waiting it out.
FAQ
How common is hair loss on GLP-1 drugs?
In a pooled analysis of nine clinical studies covering 4,114 people on a GLP-1 drug, 3.9 percent reported hair loss. The authors of a large BMJ study in adults with type 2 diabetes called the absolute risk low.
Is it the drug or the weight loss?
The studies don’t answer that. The BMJ study found an association in health records, and neither paper’s summary identifies a cause.
Does the hair grow back?
Neither study’s summary reports on regrowth. The BMJ study found the link in non-scarring hair loss, the kind where the follicle stays intact. Your own outlook is a question for a dermatologist who can look at your scalp.
Should I stop my medication if my hair is thinning?
Not on your own. Talk to the clinician who prescribed it. The BMJ authors’ point was that knowing about this possible effect can help inform treatment decisions, and those are made with your doctor.
Do the findings apply to people taking a GLP-1 drug for weight loss?
The BMJ study only included adults with type 2 diabetes, so it can’t say. The pooled analysis did find a higher rate of reported hair loss than placebo in randomized trials of people with overweight or obesity.
Will a thickening shampoo or scalp serum help?
Not with the shedding itself. Gentle hair care keeps your scalp comfortable and limits breakage, and a thickening styler makes hair look fuller for the day.
Bottom line
The research points in one direction: hair loss turns up more often in people taking GLP-1 drugs than in comparison groups, by about 37 to 68 percent against two other diabetes drugs in one large records study, and at a rate of 3.9 percent in pooled clinical studies. It also carries a clear caveat from its own authors, which is that the absolute risk is low. None of it proves the drug is the cause, and none of it is a reason to change a prescription without your doctor. Be kind to your hair in the meantime. There’s more in our hair care archive.
